manchester

OPTIMAL

 

The objective of OPTIMAL is to assess the superiority of an IVUS-guided approach versus a qualitative angio-guided approach in the setting of left-main PCI. A total of 800 participants will be randomized in a 1:1 fashion to IVUS-guided PCI versus qualitative angio-guided PCI.

The Principal Investigators are Professor Adrian Banning (United Kingdom)  and Dr. Luca Testa (Italy).

The European Cardiovascular Research Institute (ECRI) is the Sponsor for the OPTIMAL trial. ECRI is being supported by scientific grants from Boston Scientific (Marlborough, Massachusetts, USA) and Philips Volcano (Zaventem, Belgium).

The OPTIMAL trial is registered at ClinicalTrials.gov: NCT04111770